Australian Broker Call *Extra* Edition – Oct 22, 2024

This story features BANNERMAN ENERGY LIMITED, and other companies. For more info SHARE ANALYSIS: BMN

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

BMN   BOQ   CGF   COE   DUG   EBR   EVN   IPH   LAM   OFX   ORA   QOR   RIO   TLX   TWE  

BMN    BANNERMAN ENERGY LIMITED

Uranium – Overnight Price: $3.34

Canaccord Genuity rates ((BMN)) as Speculative Buy (1) –

Canaccord Genuity notes Bannerman Energy continues to progress at its Etango-8 development in Namibia with the aim of a positive final investment decision in 2025.

After completing the construction of water supply and site access road, the company is now moving to the next phase of the path towards contract awards. Management continues to assess various debt funding and potential offtake and JV opportunities.

Speculative Buy rating and $4.33 target retained. 

This report was published on October 17, 2024.

Target price is $4.33 Current Price is $3.34 Difference: $0.99
If BMN meets the Canaccord Genuity target it will return approximately 30% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 6.04 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 55.29.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 5.44 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 61.43.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

BOQ    BANK OF QUEENSLAND LIMITED

Banks – Overnight Price: $6.97

Jarden rates ((BOQ)) as Neutral (3) –

Jarden assesses Bank of Queensland reported better than expected 2H24 results. An improvement in net interest margins  was noted with a weakening in pressure on deposits and mortgage retention. Bad and doubtful debts were also better than expected.

The analyst points to flat costs in FY25 which translates into a reduction of -4% year-on-year.

Jarden raises EPS estimates by around 4% in FY25 and 1% in FY26. 

Neutral rating unchanged. Target price rises to $6.20 from $6.

This report was published on October 17, 2024.

Target price is $6.20 Current Price is $6.97 Difference: minus $0.77 (current price is over target).
If BOQ meets the Jarden target it will return approximately minus 11% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $5.53, suggesting downside of -20.7%(ex-dividends)
The company’s fiscal year ends in August.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 35.00 cents and EPS of 48.20 cents.
At the last closing share price the estimated dividend yield is 5.02%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.46.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 46.3, implying annual growth of 6.8%.
Current consensus DPS estimate is 33.8, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 15.1.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 38.00 cents and EPS of 55.60 cents.
At the last closing share price the estimated dividend yield is 5.45%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.54.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 49.8, implying annual growth of 7.6%.
Current consensus DPS estimate is 35.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 14.0.

Market Sentiment: -0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CGF    CHALLENGER LIMITED

Wealth Management & Investments – Overnight Price: $6.21

Jarden rates ((CGF)) as Overweight (2) –

Jarden points to strength in Lifetime and Japanese annuities offsetting weakness in short term fixed annuity sales for Challenger at 1Q25 results.

Adjusting for reinvestments and excluding the impact of Aware Super, the analyst estimates the total length of life sales rose to 3.9 years from 3.1 years in the quarter, year-on-year.

The broker lifts EPS forecast by 0.6% in FY25 and 5% in FY26. Overweight. Target price lifts to $8.10 from $7.90.

This report was published on October 16, 2024.

Target price is $8.10 Current Price is $6.21 Difference: $1.89
If CGF meets the Jarden target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $7.81, suggesting upside of 25.8%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 26.40 cents and EPS of 61.30 cents.
At the last closing share price the estimated dividend yield is 4.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.13.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 59.2, implying annual growth of 211.9%.
Current consensus DPS estimate is 27.9, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 10.5.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 28.30 cents and EPS of 66.00 cents.
At the last closing share price the estimated dividend yield is 4.56%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.41.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 63.5, implying annual growth of 7.3%.
Current consensus DPS estimate is 29.5, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 9.8.

Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

COE    COOPER ENERGY LIMITED

Crude Oil – Overnight Price: $0.19

Canaccord Genuity rates ((COE)) as Buy (1) –

Canaccord Genuity highlights a boost in Orbost production of 22% in 1Q25 with the “unthinkable” happening: Cooper Energy is looking at de-bottlenecking opportunities.

The broker notes higher production permitted the company to generate increased spot sales at slightly higher prices.

Forecast production increases which places Canaccord Genuity at the upper end of the guidance range, the analyst highlights.

Target price lifts to 31c from 30c. Buy rating retained.

This report was published on October 17, 2024.

Target price is $0.31 Current Price is $0.19 Difference: $0.12
If COE meets the Canaccord Genuity target it will return approximately 63% (excluding dividends, fees and charges).
Current consensus price target is $0.27, suggesting upside of 39.5%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 95.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 0.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 23.8.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.6, implying annual growth of 225.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 7.3.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

DUG    DUG TECHNOLOGY LIMITED

Cloud services – Overnight Price: $1.89

Wilsons rates ((DUG)) as Overweight (1) –

Wilsons attributes the “lumpiness” of contract wins as the cause of lower-than-expected 1Q25 trading update from Dug Technology. Revenue fell -22% on the quarter from a big contract awarded in 1Q24.

The analyst believes the strong slant to 2H25 earnings increases the risk profile, but potentially opens upside surprises to FY26.

Wilsons reiterates an Overweight rating despite lowering EBITDA estimates by -16% in FY25 and -26% in FY26.

Dug Technology raised $35m at $1.90 per share. The funds are targeted for $19m in data centre infrastructure, $6.5m in Middle East expansion and $3m in Dug Nomad with $1.5m for the cost of raising, the broker notes. Target price at $3.23.

This report was published on October 18, 2024.

Target price is $3.23 Current Price is $1.89 Difference: $1.34
If DUG meets the Wilsons target it will return approximately 71% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 118.12.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 35.66.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EBR    EBR SYSTEMS INC

Medical Equipment & Devices – Overnight Price: $1.04

Wilsons rates ((EBR)) as Overweight (1) –

Wilsons notes EBR Systems raised $50m to help fund activities for the FDA approval which is expected in March 2025.

The analyst maintains an Overweight rating and stresses the current target price of $1.62 can increase to $3 on the back of immediate “PMA-enabled indications” developing over the next 12-18 months.

Wilsons states WiSE tecnhology has the scope to move into the growing population of pacemaker patients who required left ventricular pacing.

This report was published on October 17, 2024.

Target price is $1.62 Current Price is $1.04 Difference: $0.58
If EBR meets the Wilsons target it will return approximately 56% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 23.56 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 4.41.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 14.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 7.03.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EVN    EVOLUTION MINING LIMITED

Gold & Silver – Overnight Price: $5.30

Goldman Sachs rates ((EVN)) as Neutral (3) –

Evolution Mining’s 1Q gold production and sales were broadly in line with forecasts by Goldman Sachs and consensus.

Management’s FY25 production guidance remains on track for 710-780koz at a cost (AISC) of between $1,475-1,575/oz.

The target falls by -1% to $4.50. Neutral

This report was published on October 17, 2024.

Target price is $4.50 Current Price is $5.30 Difference: minus $0.8 (current price is over target).
If EVN meets the Goldman Sachs target it will return approximately minus 15% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.45, suggesting downside of -16.0%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Goldman Sachs forecasts a full year FY25 dividend of 9.50 cents and EPS of 32.80 cents.
At the last closing share price the estimated dividend yield is 1.79%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.16.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 31.4, implying annual growth of 42.6%.
Current consensus DPS estimate is 10.9, implying a prospective dividend yield of 2.1%.
Current consensus EPS estimate suggests the PER is 16.9.

Forecast for FY26:

Goldman Sachs forecasts a full year FY26 dividend of 8.50 cents and EPS of 25.70 cents.
At the last closing share price the estimated dividend yield is 1.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.62.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 35.1, implying annual growth of 11.8%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 15.1.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

IPH    IPH LIMITED

Legal – Overnight Price: $5.48

Goldman Sachs rates ((IPH)) as Buy (1) –

After the analysts at Goldman Sachs allow for the Bereskin & Parr acquisition and associated equity raise, the target for IPH falls by -9% to $7.50.

While the equity raising helps reduce debt it also opens the opportunity to pursue M&A in adjacencies, notes Goldman. Management has previously flagged this potential including the chance to enter a new secondary market.

After recent share price underperformance, the broker suggests the current valuation is compelling for a stable, cash-generative business with solid mid-single-digit organic EPS growth and an attractive dividend yield. Buy.

This report was published on October 17, 2024.

Target price is $7.50 Current Price is $5.48 Difference: $2.02
If IPH meets the Goldman Sachs target it will return approximately 37% (excluding dividends, fees and charges).
Current consensus price target is $7.97, suggesting upside of 45.3%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Goldman Sachs forecasts a full year FY25 dividend of 36.00 cents and EPS of 47.00 cents.
At the last closing share price the estimated dividend yield is 6.57%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.66.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 46.8, implying annual growth of 86.6%.
Current consensus DPS estimate is 36.4, implying a prospective dividend yield of 6.6%.
Current consensus EPS estimate suggests the PER is 11.7.

Forecast for FY26:

Goldman Sachs forecasts a full year FY26 dividend of 39.00 cents and EPS of 51.00 cents.
At the last closing share price the estimated dividend yield is 7.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.75.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 50.3, implying annual growth of 7.5%.
Current consensus DPS estimate is 37.5, implying a prospective dividend yield of 6.8%.
Current consensus EPS estimate suggests the PER is 10.9.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

LAM    LARAMIDE RESOURCES LIMITED

Uranium – Overnight Price: $0.79

Canaccord Genuity rates ((LAM)) as Initiation of coverage with Speculative Buy (1) –

Canaccord Genuity initiates coverage of Laramide Resources with a Speculative Buy rating and $1.30 target price.

The analyst highlights the company has five uranium assets around the globe, including two 100% owned flagship projects; Crownpoint-Churchrock in New Mexico and Westmoreland in Queensland with a 117mlb resource base.

Only one more permit is required for Churchrock which has an estimated 32-year mine life producing 1mlbs per annum and scope to upscale to 3mlbs annually.

Westmoreland has estimated production of over 4mlbs a year.

Speculative Buy rating. Target price $1.30.

This report was published on October 21, 2024.

Target price is $1.30 Current Price is $0.79 Difference: $0.51
If LAM meets the Canaccord Genuity target it will return approximately 65% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 2.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 34.35.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 3.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 25.48.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

OFX    OFX GROUP LIMITED

Diversified Financials – Overnight Price: $1.39

Wilsons rates ((OFX)) as Overweight (1) –

OFX Group reported a “disappointing” 1Q25 trading update which Wilsons describes as UK and California performance “experiencing a spell of the Yips”. A golf analogy for you just can sink a put!

This is a stark change from August updates although some stablisation in the regions has been observed recently. Guidance for net operating income is inferred at over $223m for FY25, which is down around -2% on the previous corresponding period.

Wilsons lowers EPS forecasts by -19% and -18% for FY25/FY26. Wilsons has not included any US election benefits in the forecasts.

Overweight rating maintained. Target price moves to $2.11.

This report was published on October 18, 2024.

Target price is $2.11 Current Price is $1.39 Difference: $0.725
If OFX meets the Wilsons target it will return approximately 52% (excluding dividends, fees and charges).
The company’s fiscal year ends in March.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 12.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.82.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 16.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.66.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ORA    ORORA LIMITED

Paper & Packaging – Overnight Price: $2.60

Goldman Sachs rates ((ORA)) as No Rating (-1) –

Key takeaways for Goldman Sachs from Orora’s AGM include signs of recovery in the 2H Saverglass order book for North America, though management expects ongoing volume softness in Europe.

Overall, the earnings (EBIT) outlook remains consistent with management’s view in August, with some volume softness offset by cost management, explains the broker.

Goldman Sachs is currently restricted from a rating or target price.

This report was published on October 17, 2024.

Current Price is $2.60. Target price not assessed.
Current consensus price target is $2.61, suggesting upside of 0.5%(ex-dividends)

Forecast for FY25:

Current consensus EPS estimate is 15.2, implying annual growth of 2.5%.
Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 3.8%.
Current consensus EPS estimate suggests the PER is 17.1.

Forecast for FY26:

Current consensus EPS estimate is 17.6, implying annual growth of 15.8%.
Current consensus DPS estimate is 11.4, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 14.8.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

QOR    QORIA LIMITED

Software & Services – Overnight Price: $0.45

Canaccord Genuity rates ((QOR)) as Buy (1) –

Canaccord Genuity observes Qoria reported an “impressive” 1Q25 result. Annual recurring revenue advanced 17% year-on-year, boosted by new logo and existing customer growth. Free cash flow expanded to $9m from $4m in the previous year.

Management’s FY25 guidance is for EBITDA margins between 10% to 15%, inferring EBITDA of $32m-$38m the broker states.

Canaccord Genuity lifts EBITDA forecasts by 10% in FY25 and 6% in FY26.

Target price rises to 55c from 50c. No change to Buy rating.

This report was published on October 16, 2024.

Target price is $0.55 Current Price is $0.45 Difference: $0.1
If QOR meets the Canaccord Genuity target it will return approximately 22% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 22.50.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 45.00.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RIO    RIO TINTO LIMITED

Bulks – Overnight Price: $119.81

Goldman Sachs rates ((RIO)) as Buy (1) –

Rio Tinto’s 3Q production of iron ore, aluminium and copper fell around -2-3% short of forecasts by Goldman Sachs while bauxite and alumina production were beats. Pilbara iron ore shipments of 84.5mt were in line with consensus.

Management left 2024 production guidance unchanged except for lowering output for Iron Ore company of Canada (IOC) following a site-wide shut down in mid-July due to forest fires.

Goldman Sachs remains Buy-rated with a $136.20 target, down from $137.90.

This report was published on October 17, 2024.

Target price is $136.20 Current Price is $119.81 Difference: $16.39
If RIO meets the Goldman Sachs target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $126.83, suggesting upside of 5.9%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY24:

Goldman Sachs forecasts a full year FY24 dividend of 513.52 cents and EPS of 856.37 cents.
At the last closing share price the estimated dividend yield is 4.29%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.99.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1023.6, implying annual growth of N/A.
Current consensus DPS estimate is 616.8, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 11.7.

Forecast for FY25:

Goldman Sachs forecasts a full year FY25 dividend of 573.93 cents and EPS of 953.03 cents.
At the last closing share price the estimated dividend yield is 4.79%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.57.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1074.1, implying annual growth of 4.9%.
Current consensus DPS estimate is 664.6, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 11.2.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TLX    TELIX PHARMACEUTICALS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $21.49

Wilsons rates ((TLX)) as Overweight (1) –

Wilsons observes Telix Pharmaceuticals reported better than forecast 3Q24 revenue at $201m and 2024 revenue guidance was retained at $745m-$776m.

The company also announced patients are being enrolled at US sites in ProstACT Global.

Overweight rating maintained with a $25 target price.

This report was published on October 18, 2024.

Target price is $25.00 Current Price is $21.49 Difference: $3.51
If TLX meets the Wilsons target it will return approximately 16% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 19.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 110.77.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 22.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 94.67.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TWE    TREASURY WINE ESTATES LIMITED

Food, Beverages & Tobacco – Overnight Price: $11.61

Goldman Sachs rates ((TWE)) as Buy (1) –

Goldman Sachs assesses the latest Nielsen data on US wine sales trends show mixed outcomes for Treasury Wine Estates.

On the one hand, the four weeks trend (ending October 5) in 19Crimes shows modestly negative pricing and volume. On the other hand, there is clear improvement from weak July trade, points out the broker.

Overall, the analysts consider the data are in line with expectations for overall group’s (ex Daou) America performance.

Buy rating and $15.20 target.

This report was published on October 17, 2024.

Target price is $15.20 Current Price is $11.61 Difference: $3.59
If TWE meets the Goldman Sachs target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $13.71, suggesting upside of 18.1%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Goldman Sachs forecasts a full year FY25 dividend of 42.00 cents and EPS of 60.00 cents.
At the last closing share price the estimated dividend yield is 3.62%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.35.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 61.7, implying annual growth of 385.8%.
Current consensus DPS estimate is 41.4, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY26:

Goldman Sachs forecasts a full year FY26 dividend of 50.00 cents and EPS of 71.00 cents.
At the last closing share price the estimated dividend yield is 4.31%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.35.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 71.5, implying annual growth of 15.9%.
Current consensus DPS estimate is 48.1, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 16.2.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Click to view our Glossary of Financial Terms